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Purpose: Excess body weight has been associated with increased risk of 13 cancer types
and is a particularly strong risk factor for endometrial cancer (EC). Only a few previous
studies have assessed the relationship between excess body weight and EC subtypes. In this
study, we aimed to investigate the associations between excess weight and incidence of type
1 and type 2 EC.
Patients and Methods: We used data from 151,537 participants in the Norwegian Women
and Cancer (NOWAC) cohort of which 935 were diagnosed with type 1 and 263 with type 2
EC during follow-up. Height and body weight were self-reported. Multivariable Cox propor-
tional hazard regression was used to assess the associations between body mass index (BMI)
and type 1 and type 2 EC.
Results: For every 2 kg/m2 increase in BMI, the risk of type 1 EC increased by 21%
(HR=1.21, 95% CI: 1.18, 1.24) and the risk of type 2 EC by 10% (HR=1.10, 95% CI: 1.03,
1.16) (pheterogeneity = 0.009). During the period 1991 to 2016, 24.0% (95% CI: 20.0% to
27.8%) of type 1 EC cases was attributable to excess body weight. Avoiding obesity could
have prevented 6.6% (95% CI: 3.4% to 9.7%) of type 2 EC cases.
Conclusion: Excess body weight was associated with both type 1 and type 2 EC in a dose-
dependent manner and the association was significantly stronger in type 1 EC. These findings
could support the hypothesis that estrogen plays a more important role in the development of
type 1 ECs than in type 2 EC.
Keywords: obesity, overweight, cancer of the corpus uteri, uterus cancer, subtypes, body
fatness
Introduction
Over the last 40 years, the prevalence of obesity (body mass index [BMI] ≥30.0 kg/m2)
has nearly tripled worldwide and reached 39% in adults in 2016.1 Norway is no
exception, and the latest regional health examinations in Northern Norway reported
an obesity prevalence of 20.9% in men and 18.5% in women in 2007–08.2 Similar or
higher estimates have been reported from another regional health survey in Norway.3
Excess body weight, here defined as body mass index (BMI) ≥25.0 kg/m2, is a
risk factor for several lifestyle diseases including different types of cancer.4
Endometrial cancer (EC) stands out to have a particularly strong association with
excess weight.4–7 EC is traditionally divided into two main subtypes, type 1 and
type 2 EC, based on differences in clinical and histological observations.8 This
dualistic model describes in general two pathways of carcinogenesis; however, the
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classification into type 1 and type 2 EC has been debated
and new methods like immunohistochemical and genetic
analyses have challenged this simplistic categorization.9
Previous research has reported differences in risk factors
between the two subtypes, including excess body weight;
however, several studies had also limited sample size
which restrained their ability to address the associations
with type 2 EC.10–16 A recent meta-analysis concluded that
there are highly suggestive evidence for an association
between obesity and type 1 and type 2 EC.17 Others
have called for more studies addressing the associations
between obesity and histological and molecular subtypes
of EC.7 As the prognosis of the two subtypes are vastly
different and the prevalence of overweight and obesity
continues to increase, further investigations of the associa-
tions between excess body weight and subtype-specific EC
in large prospective cohort studies are highly relevant.
Thus, the main aim of this study was to assess the associa-
tions between excess body weight and type 1 and type 2
EC, in a large population-based cohort of Norwegian
women.
Patients and Methods
Study Design and Participants
The Norwegian Women and Cancer (NOWAC) study is
a national population-based cohort study initiated in 1991
with the aim of exploring associations between lifestyle and
cancer among Norwegian women.18 Women aged 30–70
years were randomly selected from the National Registry
and invited to participate in the study through a mailed
invitation letter to their home address that also included a
detailed questionnaire. The overall response rate in NOWAC
was 53% and the external validity has been proven to be
good.19
Totally 172,472 women completed the first question-
naire in 1991–2007 and were qualified for inclusion in the
study. Participants who died or emigrated before the start
of follow-up (n=31), past or prevalent cancer cases (other
than non-melanoma skin cancer) at enrolment (n=6681),
women reporting hysterectomy (n=9992) and those with
missing information on height and/or weight (n=4124)
were excluded. Further, women with implausible informa-
tion on age at menarche (<8 years or >20 years), age at
first birth (<12 years), age at menopause (<25 years or >60
years) (n=108), height or weight (height <100 cm or >230
cm; weight <30 kg or >200 kg) (n=4) were also excluded.
Thus, the final study sample included 151,532 women
from whom complete information about height and weight
at baseline were available (Figure 1).
Cancer Incidence, Death, and Emigration
The NOWAC study receives annual updates from the
Cancer Registry of Norway in order to identify study
participants diagnosed with cancer during the preceding
year. Information on the date of diagnosis and histology of
the tumor is also included. In the present study, women
diagnosed with a first primary invasive malignant neo-
plasm of the uterus (International Classification of
Diseases 10th Revision [ICD-10]: C54) were identified.
Endometrial cancer cases were identified from morphol-
ogy codes 8380, 8382, 8480, 8481, 8560, 8570, 8020,
8041, 8045, 8255, 8310, 8441, 8460 or 8323 from the
Figure 1 Flowchart of study participants.
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International Classification of Disease for Oncology ICD-
O-3. The classification into type 1 and type 2 EC was
based on the FIGO Cancer report about cancer of the
corpus uteri, the WHO Classification of Tumors as well
as literature reviews.20,21 Type 1 EC grade 3+ tumors were
classified as type 2 EC. Information about deaths and
emigration was extracted from the Causes of Death
Registry and the National Registry. The end of follow-up
was December 31, 2016.
Assessment of Body Mass Index and
Covariates
BMI was calculated from self-reported information on
weight and height and categorized into four groups: under-
weight; BMI <18.5 kg/m2, normal weight; 18.5≤ BMI <25.0
kg/m2, overweight; 25.0 ≤ BMI <30.0 kg/m2 and obesity
BMI >30.0kg/m.222 Cigarette smoking (never, ever and cur-
rent smoking), diabetes mellitus (DM; no, yes), physical
activity (PA) level (low, medium and high), coffee consump-
tion (1 to <4, ≥4 to <8, ≥8 cups/day), education level
(<10 years, 10–12 years and >12 years), age at menarche
(≤12 years, 13–14 years and ≥15 years), menopausal status
(premenopausal, perimenopausal, postmenopausal and
unknown), use of oral contraceptives (OC, never, ever), use
of hormonal intrauterine device (IUD, never, ever) and
menopausal hormone therapy (MHT, never, ever) were con-
sidered as potential covariates. In addition, we included
information about hormonal intrauterine device (IUD) and
a combined variable of age at first full-term pregnancy and
parity (nullipara; age at first birth <30 years and one child;
age at first birth ≥30 years and one child; two or more
children and age at first birth <30 years and two or more
children and age at first birth ≥30 years).
Statistical Analysis
Differences in demographics and lifestyle across BMI
categories at baseline were assessed with one-way
ANOVA, t-tests and chi-square tests. Cox proportional
hazard regressions were used to explore the associations
between BMI as continuous and categorical exposure
metrics and the incidence rates of type 1 and type 2 EC
while controlling for potential confounding variables. Age
was used as timescale. Entry time was age at inclusion,
and exit time was age at cancer diagnosis, death, emigra-
tion, hysterectomy or end of follow-up, whichever
occurred first. To determine which covariates to include
in the two regression models, we drew a directed acyclic
graph (DAG) including excess body weight, PA, smoking,
DM, coffee consumption, education, age at menarche,
parity combined with age at first birth, menopause status,
OC, IUD, MHT, and EC (Figure 2). The DAG assumes
a causal effect of excess body weight on EC, indicated by
the direct arrow from excess body weight to EC.23 We
assumed that age, PA, smoking, menopausal status, age at
first birth/parity and education were common causes of
excess body weight and EC (confounders), and were there-
fore included in the regression models. Age at menarche
was related to excess body weight during adulthood via
the unmeasured variable “excess body weight during
childhood” but had no direct effect on adult excess body
weight. However, to close the backdoor path “adult excess
body weight-excess body weight during childhood-age at
menarche- EC”, we had to adjust our models for age at
menarche. The other variables (IUD, DM, OC, MHT,
coffee consumption) were mediators and not included in
the regression models. For instance, we assumed that
excess body weight is a cause of DM that in turn increases
the risk of EC.
We fitted one regression model per EC subtype. Women
who were diagnosed with another EC type were censored at
the time of diagnosis (standard competing risk framework).
To test for linear trend across BMI groups, the group iden-
tifier was replaced by the median BMI of each group and
included in the multivariable models. To evaluate whether
the association between excess body weight and EC varied
between type 1 and type 2 EC, we used a chi-squared
(contrast) test.24 Additionally, to model the relationship
between EC risk and BMI in continuous scale and to
allow for non-linear effects, we fitted regression models
with natural cubic spline transformations (4 knots) of the
exposure variable (BMI). The knots were placed at equally
spaced percentiles. We evaluated non-linearity by testing
the null hypothesis of the second and third spline coeffi-
cients jointly equalled zero. Due to the limited number of
type 2 EC cases, we did not evaluate interactions.
Participants were excluded from the analysis if they had
missing information on any of the included variables.
Departures from the proportional hazard assumption were
assessed by inspection of the Schoenfeldt’s residuals and
Nelson-Aalen plots.
We performed two sensitivity analyses based on different
definitions of type 1 and type 2 EC. The first sensitivity
analysis categorized all type 1 EC with grade 3+ as type 1
EC, instead of as type 2 EC.13,14,25,26 The second sensitivity
analysis grouped all tumors with morphology code 8140
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(EC-not other specified [NOS]) as type 1 EC, except all
grade 3+ tumours that were classified as type 2 EC.10,25,26
By assuming a causal relationship between exposure
and outcome as well as independence between risk factors,
it is possible to estimate the population attributable frac-
tion (PAF) in a national representative cohort like the
NOWAC study. PAF describes the preventable proportion
of the disease incidence related to the exposure over
a certain time-period.27 To estimate the burden of type 1
and type 2 EC attributable to excess body weight, we
calculated PAF with 95% confidence intervals using the
PUNAFCC Stata package. We estimated PAF for two
hypothetical scenarios; i) the proportion of incident cases
that could have been prevented if overweight or obese
women were of normal or underweight, and ii) the propor-
tion of incident cases that could have been prevented by
avoiding obesity.
A two-sided p-value of 0.05 or less was considered
statistically significant. All statistical analyses were per-
formed using STATA Version 15.1 (Stata Corp LLC,
Texas, USA).
Results
The majority (63.8%) of study participants were of normal
weight; 26.0% overweight, 8.1% obese and 2.1% under-
weight. Participants with excess body weight (BMI ≥ 25.0
kg/m2) were older, more likely to be never or former
smokers, less likely to be physically active, reported
higher prevalence of DM, lower coffee consumption and
lower education level than women in normal weight.
Further, women with excess body weight experienced ear-
lier menarche, were more likely to be postmenopausal,
used less often OC and more often MHT compared to
women in normal weight. There was no difference in use
of IUD between women with excess body weight and
women in normal weight (Table 1).
During the mean follow-up time of 18 years, 1489
incident cases of cancer of the corpus uteri (CUC) were
diagnosed, of which 935 were classified as type 1 EC, 263
as type 2 EC and 291 were other CUCs. The mean age at
diagnosis was 62.3 (standard deviation [SD] 7.3) years for
type 1 EC and 63.3 (SD 7.3) years for type 2 EC.
Compared with women in normal weight, women with
overweight had 49% increased risk of type 1 EC (HR=1.49,
95% CI: 1.26, 1.76) but no increased risk of type 2 EC
(HR=1.11, 95% CI: 0.81, 1.52) (pheterogeneity = 0.109).
Women with obesity had more than three times higher inci-
dence of type 1 EC (HR=3.31, 95% CI: 2.73, 4.02) and 89%
higher rate of type 2 EC (HR=1.89, 95% CI: 1.26, 2.85)
(pheterogeneity = 0.015). There were linear trends in risk esti-
mates of type 1 (ptrend<0.001) and type 2 (ptrend=0.006) EC
across BMI groups, and there were no evidence of non-linear
Figure 2 Directed acyclic graph (DAG) illustrating the assumptions about the causal relationship between excess body weight and endometrial cancer (EC). Red circles
indicate confounders, blue circles mediators/colliders. The grey circle refers to an unmeasured variable.
Abbreviations: DM, diabetes mellitus; EC, endometrial cancer; IUD, intrauterine device; MHT, menopausal hormone therapy; PA, physical activity; OC, oral contraceptives.
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Table 1 Demographic Characteristics of the Study Sample at Baselinea. The Norwegian Women and Cancer Study
Nb Underweight Normal Overweight Obesity
Number of women, n (%) 151,532 3265 (2.1) 96,654 (63.8) 39,350 (26.0) 12,263 (8.1)
Incident CUC cases c Overall 1489 13 739 450 287
Incident CUC subtype, (%) d Type 1 EC 935 69 60 62 70
Type 2 EC 263 23 19 17 15
Others 291 8 21 20 15
Characteristics at baseline
Age Mean age (SD) 45.2 (8.8) 47.7 (8.4) 51.4 (8.1) 52.2 (7.7)
Smoking % 149,755
Never 27.3 33.9 36.1 37.6
Ex 20.5 32.8 37.5 38.4
Current 52.2 33.3 26.4 24.0
Physical activity % 139,047
Low 25.1 20.1 29.4 44.9
Medium 37.0 41.5 42.5 36.9
High 37.9 38.4 28.1 18.1
Diabetes mellitus % 119,773
Yes 1.22 1.06 2.66 9.26
Coffee consumption, cup/day % 105,501
≤1 19.2 16.4 15.2 19.9
>1 and <4 28.9 32.8 32.7 31.8
≥4 and <8 32.5 37.0 39.7 36.0
≥8 19.4 13.8 12.5 12.3
Education (y) % 143,993
<10 22.7 20.3 27.5 31.3
10–12 32.2 33.8 35.0 34.7
>12 45.1 46.0 37.5 34.0
Age at menarche (y) % 149,234
≤12 21.0 25.1 32.2 41.2
13–14 51.3 54.8 51.9 46.8
≥15 27.7 20.1 15.9 12.0
Combination age at first birth and parity
(number of children/age at first birth in y) %
151,532
nulliparity 14.3 9.9 8.7 11.6
1/<30 10.2 8.2 7.4 7.8
1/≥30 5.5 4.2 3.6 3.8
≥2/<30 63.1 71.1 74.5 71.3
≥2/≥30 6.9 6.7 5.8 5.5
Menopausal status % 151,532
Premenopausal 60.2 51.8 34.7 29.0
Perimenopausal 4.9 6.5 7.8 8.6
Postmenopausal 31.3 37.4 53.6 58.8
Unknown 3.6 4.3 3.9 3.6
Oral contraceptive use % 146,457
Ever 62.2 60.4 52.4 48.2
(Continued)
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effects (Figure 3). Every 2 kg/m2 increase in BMI was
associated with 21% (HR=1.21, 95% CI: 1.18, 1.24)
increased risk of type 1 EC and 10% (HR=1.10, 95% CI:
1.03, 1.16) increased risk of type 2 EC (pheterogeneity = 0.009).
All models fulfilled the assumptions of proportional hazards.
When all type 1 ECwith grade 3+ were classified as type 1
EC, we found a significant increased risk of type 1 EC (per 2
kg/m2 increase: HR=1.19, 95%CI: 1.17, 1.22), but not of type
2 EC (HR=1.07, 95% CI: 0.98, 1.18) (pheterogeneity=0.027).
Further, when classifying all tumours with histological code
“8140” (adenocarcinoma, NOS) as type 1 EC, the risk of type
1 EC increased by 20% per 2 kg/m2 increase in BMI
(HR=1.20, 95% CI: 1.18, 1.23) and the risk of type 2 EC by
10% (HR=1.11, 95% CI: 1.04, 1.16) (pheterogeneity=0.003).
Given a causal relationship, preventing excess body
weight could have avoided 24.1% (95% CI: 20.1% to
28.0%) of type 1 EC cancers among Norwegian women
from 1991 to 2016. If women with obesity had been of
over-, normal- or underweight, 13.5% (95% CI: 12.2% to
14.9%) of type 1 EC could have been prevented. The esti-
mate for the proportion of avoidable type 2 EC cases by
preventing excess body weight was 9.4% (95% CI: 0.0% to
18.2%), whereas avoiding obesity could have prevented
6.6% (95% CI: 3.4% to 9.7%) of type 2 EC cases (Table 3).
Discussion
In this study of 151,532 women from Norway, we found that
excess body weight was associated with both type 1 and type
2 EC in a dose-dependent manner. For each 2 kg/m2 increase
in BMI, the incidence rates of type 1 and type 2 EC
increased by 21% and 10%, respectively, and the association
was significantly stronger in type 1 EC than in type 2 EC.
Assuming a causal effect of excess body weight on EC, we
estimated that almost every fourth case of type 1 EC in
Norway in 1991–2016 could have been prevented, if
women had avoided excess weight. For type 2 EC, almost
7% of the disease incidence in that same period was attribu-
table to obesity. The PAF estimate for type 2 EC for the
Figure 3 Associations between body mass index (BMI) and (A) type 1 and (B) type 2 endometrial cancer (EC). BMI is modelled as a continuous exposure metric using
restricted cubic spline transformations with 4 knots. The p-value corresponds to the null hypothesis that the regression coefficient for the second and third spline
transformations equaled zero, ie, a test of non-linearity.
Table 1 (Continued).
Nb Underweight Normal Overweight Obesity
IUD use % 108,182
Ever 7.0 10.0 10.2 9.9
MHT use % 142,570
Ever 16.1 21.7 27.7 26.2
Notes: aAll differences between BMI category were statistically significant (p<0.05), except for IUD use: bTotal number per variable: cIncident CUC cases among the study
population in the observation period from 1991 until December 31st 2016: d% of total CUC in each BMI category.
Abbreviations: SD, standard deviation; y, years.
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modification of overweight and obesity to normal/under-
weight was borderline significant, clearly driven by the
non-significant association between overweight and type 2
EC (Tables 2 and 3). Important, our baseline questionnaire
was collected in 1991–2008 and the prevalence of obesity
among the participants was only 8% by that time, which is
relatively low compared to more recent numbers reported
from regional health examinations in Norway.2,3 As the PAF
is dependent on the prevalence of exposure, one could
expect a larger impact of excess body weight on the burden
of type1 and type 2 EC today and in the future. Thus, our
results clearly emphasize the preventive potential of main-
taining a healthy weight, also in regards to type 2 EC, which
has a much poorer prognosis than type 1 EC.1–3
Our results of positive and significant associations
between excess body weight and both type 1 and type 2
EC, and a significantly stronger association with type 1
EC, are in line with several previous studies.11,12,14,15,28–30
For instance, in a pooled analysis with individual-level
data from 24 studies, Setiawan and colleagues showed
that BMI was significantly and positively associated with
both type 1 and type 2 ECs, and that the association was
significantly stronger in type 1 EC.10 Additionally, a recent
meta-analysis also concluded that both subtypes are asso-
ciated with obesity.17 Collectively, our results clearly
indicate that excess body weight is a risk factor not only
for type 1 EC but also for type 2 EC. The fact that the
association seems stronger in type 1 EC may indicate that
estrogens are more important for the development of type
1 EC than for type 2.
A challenge when studying risk factors for EC sub-
types is the classification of EC into type 1 and type 2 as
there is no common definition. In this study, we classified
all type 1 ECs with grade 3+ as type 2 EC, in addition to
the type 2 tumors confirmed by histology, in accordance
with recommendations from the American Cancer Society,
the FIGO cancer report and several other reports.31–34
From a clinical point of view, grade 3+ tumors behave
like type 2 ECs, as they are more aggressive than grade 1
and grade 2 endometrioid ECs. Nevertheless, we con-
ducted two sensitivity analyses to explore the effects of
different classifications. When all tumors were classified
according to their histological profile and the grade was
not taken into account, we observed a significantly stron-
ger association between BMI and type 1 EC compared to
type 2 EC (pheterogeneity=0.027). However, BMI was no
longer significantly associated with type 2 EC HR=1.07
(95% CI: 0.98, 1.17), which may be explained by the
considerably smaller number of type 2 tumors using this
classification (n=103) compared to the other (n=218). This
Table 2 Multivariable Adjusted Hazard Ratios (HRs)a with 95% Confidence Intervals (CIs) for the Associations Between BMI and
Incidence of Type 1 and Type 2 Endometrial Cancer (EC)
Type 1 EC Type 2 EC
BMI (kg/m2) n Person-years n cases HR (95% CI) p c n cases HR (95% CI) p c Pheterogneity
b
Underweight, <18.5 2762 53,005 7 0.61 (0.29, 1.29) 0.199 3 0.83 (0.26, 2.61) 0.748
Normal weight, 18.5–24.9 83,816 1,483,261 382 1.00 123 1.00
Overweight, 25.0–29.9 33,352 518,462 238 1.49 (1.26, 1.76) <0.001 60 1.11 (0.81, 1.52) 0.525 0.109
Obesity, ≥30 10,228 149,545 166 3.31 (2.73, 4.02) <0.001 32 1.89 (1.26, 2.85) <0.001 0.015
Ptrend
d <0.001 0.006
BMI (per 2 kg/m2) 130,158 2,204,273 793 1.21 (1.18, 1.24) <0.001 218 1.10 (1.03, 1.16) 0.003 0.009
Notes: aMultivariable cox regression model adjusted for physical activity, education, age at first birth and parity, menopausal status, smoking and age at menarche: bP
heterogeneity between the estimate for type 1 and type 2 EC:
cP for H0: HR = 1;
dp trend for trend across BMI categories.
Abbreviations: HR, hazard ratio; CI, confidence interval; BMI, body mass index; EC, endometrial cancer.
Table 3 Population Attributable Fractions (PAF) and 95% Confidence Intervals (CI) of Type 1 and 2 Endometrial Cancer (EC) in
Women in Norway in 1991–2016 Attributable to Excess Body Weight and Obesity
Modification of Excess Body Weight to Normal/underweight Modification of Obesity to Non-obesity
PAF (%) (95% CI) HR (95% CI) PAF (%) (95% CI) HR (95% CI)
Type 1 EC 24.1 (20.1, 28.0) 1.90 (1.64, 2.20) 13.5 (12.2, 14.9) 2.83 (2.37, 3.39)
Type 2 EC 9.4 (0.0, 18.2) 1.29 (0.97, 1.71) 6.6 (3.4, 9.7) 1.82 (1.23, 2.69)
Notes: Multivariable cox regression model adjusted for physical activity, education, age at first birth and parity, menopausal status, smoking and age at menarche.
Abbreviations: PAF, population attributable fraction; HR, hazard ratio; CI, confidence interval; EC, endometrial cancer.
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is in line with McCollough et al that observed a positive
association between BMI and type 2 EC, although the
association was driven by high-grade endometrioid tumors
(type 1 grade 3 tumors) that were classified as type 2 EC.
There was a low number of type 2 tumors determined from
histology only, which limited further analyses in that
study.11
In our second sensitivity analysis, 8140 (adenocarcinoma
NOS) tumors were classified as type 1 EC, whereas in the
main analysis they were excluded. The result from this
analysis is in line with our main findings, showing positive
associations between increasing BMI and both EC subtypes,
and a significantly stronger association with type 1 EC. Thus,
in this study, the choice of including or excluding adenocar-
cinoma NOS did not affect our conclusions. However, the
previous sensitivity analysis clearly showed that the choice
of classification may have a large impact on the conclusions
from a study as we observed no significant association
between BMI and type 2 EC when grade 3+ type 1 EC
tumors were classified as type 1 EC. A crucial first step for
the classification is the histological determination by a
pathologist. Already here, the agreement between different
pathologists is moderate (the interobserver agreement for the
FIGO system κ = 0.41) and several studies have confirmed
limited reproducibility in determination of histological code
and grading of ECs.31–33,35 However, the reproducibility was
improved when a binary grading system was used that
divided tumors into low-grade and high-grade lesions. Still,
the cut-off between grades 2 and 3 is not always clear and an
objective for discussions.31,36,37 An additional challenge is
that researchers do not always describe the histological codes
and their classification in detail, which may lead to misun-
derstandings and challenges to compare results across stu-
dies. This could easily be avoided if all studies reported their
classification by means of ICD-O-3 codes.
The strengths of this study include the large and
national representative sample, the linkage to national
registries that ensures complete information about death,
emigration and cancer diagnosis and the detailed informa-
tion about sociodemographic, reproductive and lifestyle
variables that we included in our analyses. However, the
information from the Cancer Registry of Norway was
limited to the histological and morphological codes.
There were no possibilities to review the histological
slides and discuss the classification and determination of
type 1 and type 2 EC with the help of this information. For
the same reason, it was not possible to assess BMI in
relation to the distinct molecular subgroups of EC based
on the cancer genome atlas (TCGA), which could be seen
upon as a limitation of the study as type 1 and type 2 EC
have different molecular features.38
As NOWAC is representative for the general female
population, we had the opportunity to estimate PAFs for
excess body weight in relation to EC subtypes, which is
rare and provides an estimate that is easily communicated
to the public. Nevertheless, the PAF calculation did not
account for death as a competing risk, and therefore our
PAF estimates could have been slightly overestimated. It is
also important to emphasize that the PAF estimate is
derived from an observational study and not from a ran-
domized controlled trial. It should therefore be interpreted
with caution, as we cannot fully disregard that our study
was not affected by unmeasured confounding, and/or
information bias that could influence the inferences. For
instance, height and weight were self-reported which could
introduce potential misclassification. The accuracy of the
self-reported information on weight and height in
NOWAC has however been validated and discrepancies
between self-reported and directly measured BMI in
women were small.39 Despite under-reporting in the over-
weight and obese group, the authors concluded that the
self-reported weight and height data provided a valid rank-
ing of BMI of middle-aged Norwegian women. Further,
we can assume that potential misclassification of height
and weight is non-differential between EC cases and non-
cases, as the information about height and weight was
collected prior to the diagnosis of the disease.
Conclusion
This study adds to the evidence that excess body weight is
a risk factor for both type 1 and type 2 EC, although the
association is significantly stronger in type 1 EC.
Abbreviations
CI, confidence interval; CUC, cancer of the uterine corpus;
DAG, directed acyclic graphs; DM, diabetes mellitus;
BMI, body mass index; EC, Endometrial cancer; FIGO,
International Federation of Gynecology and Obstetrics;
HR, hazard ratio; ICD, International classification of dis-
eases and related health problems; ICD-O, International
classification of diseases for oncology; IUD, intrauterine
device; MHT, menopausal hormone therapy; NOWAC, the
Norwegian Women and Cancer study; OC, oral contra-
ceptives; PAF, population attributable fraction; SD, stan-
dard deviation.
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